Abstracts tagged "administrative databases"

Abstract Number: 2048 • 2015 ACR/ARHP Annual Meeting
Hospitalization Trends of Rheumatoid Arthritis and Gout in the United States: A Crossroad
Sian Yik Lim¹, Na Lu¹, Mark Fisher¹, Amar Oza¹, Sharan K. Rai², Mariano E Menendez¹ and Hyon Choi¹, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Experimental Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Rheumatoid arthritis (RA) and gout are the two most common inflammatory arthritides in the US and beyond. As hospitalization for these conditions are known…
Abstract Number: 2277 • 2014 ACR/ARHP Annual Meeting
Inpatient Pediatric Rheumatic Diseases: Characteristics, Cost and Trends
Monica Mahajan¹, Mohammad Shah², Mary Toth^3,4, Neil McNinch⁵ and Moussa El-Hallak⁶, ¹Department of Pediatrics, Akron Children's Hospital, Akron, OH, ²Patient Safety and Quality Services, Akron Children's Hospital, Akron, OH, ³Akron Children's Hospital, Akron, OH, ⁴Rheumatology, Akron Children's Hospital, Akron, OH, ⁵Rebecca D. Considine Research Institute, Akron Children's Hospital, Akron, OH, ⁶Dept of Pediatric Rheumatology, Akron Children's Hospital, Akron, OH
Background/Purpose: Childhood rheumatic diseases (cRD) have wide spectrum of complexity and disease course from mild disease to acute fulminate disease and even sudden death. Physicians…
Abstract Number: 1882 • 2014 ACR/ARHP Annual Meeting
Examination of Patients Newly Diagnosed with Fibromyalgia: Use of Guideline-Recommended Therapies and Opioids in Clinical Practice
Sonali N. Shah¹, Rachel Halpern², Joseph C. Cappelleri³, Elizabeth T. Masters⁴, Andrew G. Clair⁵, Cori Blauer-Peterson² and Damon Van Voorhis⁶, ¹Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, ²Health Economics and Outcomes Research, Optum, Eden Prairie, MN, ³Biostatistics, Pfizer, Inc., Groton, CT, ⁴Health Economics and Outcomes Research, Pfizer Inc, New York, NY, ⁵US Medical Affairs Primary Care, Pfizer, Inc., New York, NY, ⁶Optum Life Sciences, Eden Prairie, MN
Background/Purpose: Fibromyalgia (FM) affects 2-5% of adults in the United States. Pregabalin (antiepileptic drug [AED]), and duloxetine and milnacipran (serotonin and norepinephrine reuptake inhibitors), are…
Abstract Number: 1155 • 2014 ACR/ARHP Annual Meeting
Economic Impact of Frequent Gout Flares in a Managed Care Setting
Robert Jackson¹, Aki Shiozawa², Erin Buysman³, Aylin Altan³, Stephanie Korrer³ and Hyon K. Choi⁴, ¹Global Medical Office, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ²One Takeda Parkway, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ³Health Economics and Outcomes Research, Optum, Eden Prairie, MN, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose Gout is the most common inflammatory arthritis in the US. For most patients, excruciatingly painful gout attacks (“flares”) are the major clinical burden of…
Abstract Number: 116 • 2014 ACR/ARHP Annual Meeting
Is Socioeconomic Status at Diagnosis Associated with Long-Term Direct Medical Costs in Systemic Sclerosis? a General Population-Based Cohort Study
Natalie McCormick¹, Mohsen Sadatsafavi², Wenjia Chen³, Carlo A. Marra⁴ and J. Antonio Avina-Zubieta⁵, ¹Faculty of Pharmaceutical Sciences, University of British Columbia/Arthritis Research Centre of Canada, Vancouver, BC, Canada, ²Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada, ³Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁴Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: Low socioeconomic status (SES) is associated with negative health outcomes and higher healthcare costs in general populations, but the impact of SES on costs…
Abstract Number: 1067 • 2013 ACR/ARHP Annual Meeting
Incidence and Prevalence Of Systemic Lupus Erythematosus: A 2010 Nation-Wide Population-Based Study Using French National Administrative Databases
Laurent Arnaud¹, Jean-Paul Fagot², Michel Païta², Alexis Mathian³, Anne Fagot-Campagna² and Zahir Amoura⁴, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, Paris, France, ³Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁴Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: To date, only a small number of studies have examined the epidemiology of systemic lupus erythematosus (SLE) on a nation-wide basis. These studies were…
Abstract Number: 1018 • 2013 ACR/ARHP Annual Meeting
Methodology Of Determining An Appropriate Look-Back Period To Identify Autoimmune Rheumatic Disease In a Study Of Post-Myocardial Infarction Mortality
Mark Tacey, Megan Bohensky and Sharon Van Doornum, Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia
Background/Purpose: Hospital administrative datasets offer an opportunity to study the relatively rare occurrence of auto-immune rheumatic diseases (AIRD). Under-coding is a known limitation however. “Look-back”…
Abstract Number: 607 • 2013 ACR/ARHP Annual Meeting
Venous Thromboembolic Disease Is Associated With Increased Length Of Stay and In-Hospital Mortality In Hospitalized SLE Patients: A Multi-State, Population-Based Study
Matthew Cascino¹, Laura Trupin¹, Sara Murray¹, Mary Margaretten², Edward H. Yelin³ and Jinoos Yazdany¹, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) are at increased risk for venous thromboembolism (VTE). However, there is limited population-based data on outcomes associated with…
Abstract Number: 115 • 2013 ACR/ARHP Annual Meeting
Association Between History Of Periodontitis and Risk Of Rheumatoid Arthritis In Individuals With and Without Diabetes Mellitus: A Population-Based Cohort Study
Hsin-Hua Chen^1,2, D.Y. Chen¹ and Nicole Huang³, ¹Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ²nstitute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan, ³Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan
Background/Purpose: To examine whether the association between periodontitis (PD) history and the rheumatoid arthritis (RA) risk differs between individuals with and without diabetes mellitus (DM).Methods:…
Abstract Number: 2829 • 2013 ACR/ARHP Annual Meeting
Statin Adherence and Risk Of Mortality In Patients With Rheumatoid Arthritis: A Population-Based Study
Mary De Vera^1,2, Michal Abrahamowicz³ and Diane Lacaille⁴, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: Poor adherence with statin therapy is associated with increased mortality in the general population, but no corresponding data are available among patients with rheumatoid…
Abstract Number: 2679 • 2013 ACR/ARHP Annual Meeting
Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication Use
Linda T. Hiraki¹, Candace H. Feldman², Mary Beth Son³, Jessica M. Franklin⁴, Michael A. Fischer⁴, Daniel H. Solomon⁵, Seoyoung C. Kim⁶, Wolfgang C. Winkelmayer⁷ and Karen H. Costenbader², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Division of Nephrology, Stanford University School of Medicine, Stanford, CA
Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication UseBackground/Purpose: We investigated incidence rates…
Abstract Number: 1756 • 2013 ACR/ARHP Annual Meeting
Trends In Incidence and Mortality In Rheumatoid Arthritis and Systemic Autoimmune Rheumatic Diseases In Quebec, Canada: A Population-Based Study
Sonia Jean¹, Philippe Gamache², Marie Hudson³, Louis Bessette⁴, Paul R. Fortin⁵, Gilles Boire⁶ and Sasha Bernatsky⁷, ¹Chronic disease surveillence division, National Institute of public health of Quebec, Quebec, QC, Canada, ²Chronic disease surveillance division, National institute of public health of Quebec, Quebec, QC, Canada, ³Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ⁵Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ⁶Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada
Background/Purpose: Health administrative data (HAD) are a potentially efficient to conduct population-based research and are increasingly used to develop chronic disease surveillance indicators. Examining trends…
Abstract Number: 1263 • 2013 ACR/ARHP Annual Meeting
Childhood-Onset Systemic Lupus Erythematosus In Ontario: Long Term Outcomes In a Population-Based Cohort With Universal Health Care Coverage
Deborah M. Levy¹, Nadia Gunraj², Janet E. Pope³, J. Carter Thorne⁴, Wesley Fidler⁵, Peter B. Dent⁶, Johannes Roth⁷, Roberta A. Berard⁸, Murray Berall⁹, Astrid Guttmann¹⁰ and Earl D. Silverman¹¹, ¹Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Medicine/Rheumatology, St. Joseph's Health Care, University of Western Ontario, London, ON, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵Rheumatology, St. Joseph's Hospital, Thunder Bay, ON, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸Children's Hospital of Western Ontario, London, ON, Canada, ⁹Nephrology, Humber River Regional Hospital, Toronto, ON, Canada, ¹⁰Pediatrics, Institute for Clinical Evaluative Sciences, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹¹Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Little is known about the long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care; however, linking clinical data to administrative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].